Although several analgesic therapies are available to alleviate the symptoms of diabetic neuropathic pain, few options are available to eliminate the root causes and DN remains a challenge for physicians.[14] In animal studies, alpha lipoic acid (ALA) has been shown to prevent or even reverse hyperglycemia-induced nerve dysfunction by reducing free-radical-mediated oxidative stress.[15] It has also been demonstrated that ALA improves nerve blood flow and check details peripheral nerve fiber conduction and increases endoneurial glucose uptake and energy metabolism in experimental ML323 nmr diabetic peripheral neuropathy.[16]

Two meta-analyses of randomized, placebo-controlled trials using ALA infusions of 600 mg intravenously/orally per day for 3 weeks in diabetic patients with positive symptoms of peripheral neuropathy have been published[1,17] and suggest that this treatment produces clinically significant improvements in neuropathic symptoms and deficits. When given intravenously, ALA leads to a significant and clinically relevant reduction in neuropathic pain. Improvements with oral administration are less described but strongly marked after just 2 weeks of treatment.[9] Nevertheless, there are a lack of significant data on the effects of ALAs on nerve conduction velocity. Superoxide dismutase (SOD) is an essential, ubiquitous enzyme that detoxifies highly reactive O2 – by catalysis into H2O2, which in turn is

reduced in H2O in the mitochondria ATR inhibitor by glutathione peroxidase and catalase.[18] SOD, which has the important role of neutralizing superoxide radicals, is reduced

in diabetic peripheral nerve tissue, thus compounding any enhancement of free radical formation.[19–21] Furthermore, SOD has a key role in inhibiting inflammatory response, which is closely correlated with attenuation of hyperalgesia.[22] Since oxidative stress is enhanced in diabetic patients with neuropathy,[12] a pharmacologic strategy aimed at overcoming the deficit of antioxidant agents should provide significant relief from complications for neuropathic patients. The ideal treatment should prevent or arrest the progressive loss of nerve functionality and improve symptoms with minimal side effects. A new oral formulation combining ALA and SOD, two powerful antioxidant agents singly active in DN, has been proposed Dynein as a powerful tool in the treatment of DN. The aim of this pilot study was to assess changes in nerve conduction velocity and symptomatology in patients with DN treated daily for 4 months with a combination of ALA and SOD. Patients and Methods From May to November 2010, a prospective, non-randomized, open-label, pivotal study was conducted. The study population included patients with diabetes and with diabetic symmetric sensorimotor polyneuropathy.[23] Patients were treated orally for 4 months with ALA 600 mg and SOD 140 IU/day (ALA600 SOD®, Alfa Wassermann, Bologna, Italy).